Genome Opinion is a bio-startup established in 2017. Through 'Bio-Informatics' technology that can be applied to biotechnology such as preventive medicine and personalized medicine by systematically collecting, managing, storing, and analyzing genome information using computers, it is developing 'biomarker' and performing precision medicine such as diagnosis and target drug development.

Through the technology of Genome Opinion, it is about to commercialize a customized cardiovascular disease prediction model recently developed with the Seoul National University Hospital research team. Phase 2 clinical trials for new drugs related to blood cancer based on genome analysis technology are also in progress with large domestic pharmaceutical companies.

Existing investors, domestic pharmaceutical conglomerate Yuhan Corporation, as well as Mirae Asset Venture Investment, Bokwang Investment, Medici Investment, and CL Partners participated in the investment. It drew attention for attracting large-scale investment even in the venture industry, where investment in biotech companies was recently suspended.

Based on its deep understanding of the domestic venture industry, SEUM provided overall legal advice on investment contract review and investment negotiations so that this Series B investment of KRW 10 billion won could be completed smoothly.